Incidence and Predictors of Post-TIPS (Transjugular Intrahepatic Portosystemic Shunt (TIPS) Heart Failure in Patients With Cirrhosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Liver Cirrhosis
- Sponsor
- West China Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Incidence of heart failue
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
Detailed Description
Hyperdynamic circulation is a common Phenomenon in cirrhosis due to systemic and splanchnic vasodilatation, which may result cardic dysfunction and abnormal structure ,called cirrhotic cardiomyopathy(CCM). Transjugular intrahepatic portosystemic shunt (TIPS), as a effective technique to alleviates portal hypertension in cirrhotic patients, often be used to treat with refractory ascites and variceal bleeding which endoscopy and drug therapy are ineffective. However, owing to the increased shunting of blood from the splanchnic vascular bed into the central vascular bed, TIPS further exacerbates the hyperdynamic circulatory state, which may lead to heart failure.yet there are no convincing research to study the incidence of heart failure in cirrhosis after transjugular intrahepatic portosystemic shunt. The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.
Investigators
luo xuefeng
MD
West China Hospital
Eligibility Criteria
Inclusion Criteria
- •TIPS is placed successfully
- •Agree to participate in the trial
Exclusion Criteria
- •Non-cirrhotic portal hypertension
- •Previous TIPS or surgical shunt
- •Medium to severe pulmonary hypertension
- •Heart failure
- •End-stage renal disease requiring hemodialysis
- •Respiratory failure
- •Malignancies with a life expectancy of less than 6 months
Outcomes
Primary Outcomes
Incidence of heart failue
Time Frame: up to 36 months
Heart failue assessed by2021 ESC Guidelines
Secondary Outcomes
- Predictors of heart Failure(up to 36 months)
- mortality(up to 36 months)
- Modififications of cardiac function(up to 36 months)